Goldenberg Heller & Antognoli on put the spotlight on Goldenberg Heller & Antognoli, P.C. and the decision by the Judicial Panel on Multidistrict Litigation to transfer and consolidate all pending and future federal lawsuits involving the anticoagulant Pradaxa, In Re: Pradaxa Product Liability Litigation, MDL No. 2385, to the Southern District of Illinois.

The August 9, 2012 article quotes GHA as saying “In an order issued August 8, 2012, the JPML assigned the Pradaxa MDL docket No. 2385 to Judge David R. Herndon of the U.S. District Court for the Southern District of Illinois after Plaintiffs filed a petition in May seeking transfer of nearly a dozen Pradaxa personal injury and wrongful death lawsuits, specifically requesting Judge Herndon as transferee judge.”

Pradaxa, a direct thrombin inhibitor used to reduce the risk of stroke and embolism in patients with non-valvular atrial fibrillation, was approved by the FDA in October 2010. Since its approval, it has generated an abnormally high number of adverse-event reports, including 260 fatalities from people who have bled to death while using the drug.

“We believe that Pradaxa causes uncontrolled and excessive bleeding in patients taking the drug and that the manufacturer failed to warn physicians and patients that there is no effective means of reversing Pradaxa’s excessive bleeding side effects,” said GHA.

As of Dec. 31, 2011, the FDA received more than 500 reports of U.S. deaths linked to Pradaxa, according to the petition.

If you or a loved one suffered when using Pradaxa, contact Thomas J. Lech.

Share Button